» Articles » PMID: 20487220

Pharmacokinetic Interaction Between Puerarin and Edaravone, and Effect of Borneol on the Brain Distribution Kinetics of Puerarin in Rats

Overview
Specialties Pharmacology
Pharmacy
Date 2010 May 22
PMID 20487220
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: The aim was to investigate the pharmacokinetic interaction between puerarin and edaravone, and the effect of borneol on the brain distribution kinetics of puerarin in rats.

Methods: A reversed-phase high performance liquid chromatography method was developed and validated for the simultaneous determination of puerarin and edaravone in rat plasma. The detection method was successfully applied to compare the pharmacokinetic interaction and brain distribution kinetics of puerarin and edaravone using in-situ microdialysis sampling in rats after intravenous administration and co-administration with a single dose.

Key Findings: The method gave good linearity and no endogenous material interfered with the two target compounds and internal standard peaks. The limit of detection of puerarin and edaravone was 0.03 and 0.05 microg/ml, respectively. The average recovery of the two compounds from rat plasma was >94%. The precision of the test was determined to be within 10%. The combination of puerarin and edaravone reduced drug elimination rates, gave a wider distribution, and the disposition of both drugs in rats was optimized. The distribution of puerarin in brain tissues was significantly increased and its elimination was noticeably slower with borneol pretreatment.

Conclusions: The results provide important information for the improved combined use of puerarin and edaravone with borneol pretreatment in clinical practice.

Citing Articles

Osthole/borneol thermosensitive gel via intranasal administration enhances intracerebral bioavailability to improve cognitive impairment in APP/PS1 transgenic mice.

Wu F, Huang M, Zuo X, Xie R, Liu J, Ke J Front Pharmacol. 2023; 14:1224856.

PMID: 37521471 PMC: 10373789. DOI: 10.3389/fphar.2023.1224856.


Edaravone Dexborneol Alleviates Cerebral Ischemic Injury via MKP-1-Mediated Inhibition of MAPKs and Activation of Nrf2.

Zhang W, Yang H, Gao M, Zhang H, Shi L, Yu X Biomed Res Int. 2022; 2022:4013707.

PMID: 36110124 PMC: 9470337. DOI: 10.1155/2022/4013707.


Pre-Clinical Pharmacokinetic Characterization, Tissue Distribution, and Excretion Studies of Novel Edaravone Oral Prodrug, TEJ-1704.

Kang D, Kim J, Kim K, Cho S, Jang H, Chang J Pharmaceutics. 2021; 13(9).

PMID: 34575481 PMC: 8469431. DOI: 10.3390/pharmaceutics13091406.


Aerosol inhalation of edaravone can improve inflammation, oxidative stress and pulmonary function of rats with smoke inhalation injury by down-regulating miR-320.

Xiao C, Yu Y, Liu Y, Yang J Am J Transl Res. 2021; 13(4):2563-2570.

PMID: 34017415 PMC: 8129403.


Progress in Borneol Intervention for Ischemic Stroke: A Systematic Review.

Li Y, Ren M, Wang J, Ma R, Chen H, Xie Q Front Pharmacol. 2021; 12:606682.

PMID: 34017247 PMC: 8129537. DOI: 10.3389/fphar.2021.606682.